

CADILA HEALTHCARE , Lipaglyn Launched in India - Survey suggests quick market acceptance, if priced appropriately

<https://marketpublishers.com/r/CDB4A56FCDAEN.html>

Date: September 2013

Pages: 2

Price: US\$ 140.00 (Single User License)

ID: CDB4A56FCDAEN

Abstracts

Zydus today announced the launch of its novel dual PPAR agonist Lipaglyn (saroglitazar) for treatment of diabetic dyslipidemia patients not controlled by statin alone. Based on our physician survey / assessment of the drug profile / market analysis, we expect Lipaglyn to garner around INR 650 million in peak sales in India by 2016. We see the need of a fixed dose combination of Lipaglyn with statin as important for the quick ramp up for this novel compound.

I would like to order

Product name: CADILA HEALTHCARE , Lipaglyn Launched in India - Survey suggests quick market acceptance, if priced appropriately

Product link: <https://marketpublishers.com/r/CDB4A56FCDAEN.html>

Price: US\$ 140.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CDB4A56FCDAEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

